Raras
Buscar doenças, sintomas, genes...
Carcinoma da tireoide diferenciado
ORPHA:146CID-10 · C73DOENÇA RARA

O carcinoma diferenciado da tireoide (CDT), também conhecido como carcinoma papilar ou folicular da tireoide, é uma doença maligna de crescimento lento que geralmente se apresenta em adultos como uma massa tireoidiana assintomática.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O carcinoma diferenciado da tireoide (CDT), também conhecido como carcinoma papilar ou folicular da tireoide, é uma doença maligna de crescimento lento que geralmente se apresenta em adultos como uma massa tireoidiana assintomática.

Pesquisas ativas
35 ensaios
207 total registrados no ClinicalTrials.gov
Publicações científicas
4.314 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Adolescent
+ adult, childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C73
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
5 sintomas
🫃
Digestivo
4 sintomas
🩸
Sangue
4 sintomas
🦴
Ossos e articulações
3 sintomas
🫁
Pulmão
2 sintomas
🫘
Rins
2 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

Carcinoma medular de tireoide
Dor óssea
Hiperidrose
Neoplasia ovariana
Carcinoma de tireoide não medular
Neoplasia do pulmão
32sintomas
Sem dados (32)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 32 características clínicas mais associadas, ordenadas por frequência.

Carcinoma medular de tireoideMedullary thyroid carcinoma
Dor ósseaBone pain
HiperidroseHyperhidrosis
Neoplasia ovarianaOvarian neoplasm
Carcinoma de tireoide não medularNon-medullary thyroid carcinoma

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.314PubMed
Últimos 10 anos200publicações
Pico2025122 papers
Linha do tempo
2026Hoje · 2026🧪 1988Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

33 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

HRASGTPase HRasDisease-causing somatic mutation(s) inTolerante
FUNÇÃO

Involved in the activation of Ras protein signal transduction (PubMed:22821884). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:12740440, PubMed:14500341, PubMed:9020151)

LOCALIZAÇÃO

Cell membraneGolgi apparatusGolgi apparatus membraneNucleusCytoplasmCytoplasm, perinuclear region

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsEPHB-mediated forward signaling
MECANISMO DE DOENÇA

Costello syndrome

A rare condition characterized by prenatally increased growth, postnatal growth deficiency, intellectual disability, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
107.7 TPM
Skin Sun Exposed Lower leg
104.9 TPM
Esôfago - Mucosa
81.3 TPM
Cérebro - Hemisfério cerebelar
77.6 TPM
Brain Caudate basal ganglia
77.6 TPM
OUTRAS DOENÇAS (10)
nevus, epidermalthyroid cancer, nonmedullary, 2Costello syndromelinear nevus sebaceous syndrome
HGNC:5173UniProt:P01112
TRIM33E3 ubiquitin-protein ligase TRIM33Part of a fusion gene inAltamente restrito
FUNÇÃO

Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4 ubiquitination, nuclear exclusion and degradation via the ubiquitin proteasome pathway. According to PubMed:16751102, does not promote a decrease in the level of endogenous SMAD4. May act as a transcriptional repressor. Inhibits the transcriptional response to TGF-beta/BMP signaling cascade. Plays a role in the control of cell proliferation. Its association with SMAD2 and SMAD3 stimulates erythroid differentiation of hematopoietic stem/proge

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Downregulation of SMAD2/3:SMAD4 transcriptional activityGerm layer formation at gastrulation
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
26.0 TPM
Cérebro - Hemisfério cerebelar
25.6 TPM
Útero
23.2 TPM
Ovário
22.6 TPM
Nervo tibial
21.8 TPM
OUTRAS DOENÇAS (2)
differentiated thyroid carcinomadislocation of the hip-dysmorphism syndrome
HGNC:16290UniProt:Q9UPN9
NCOA4Nuclear receptor coactivator 4Part of a fusion gene inTolerante
FUNÇÃO

Cargo receptor for the autophagic turnover of the iron-binding ferritin complex, playing a central role in iron homeostasis (PubMed:25327288, PubMed:26436293). Acts as an adapter for delivery of ferritin to lysosomes and autophagic degradation of ferritin, a process named ferritinophagy (PubMed:25327288, PubMed:26436293). Targets the iron-binding ferritin complex to autolysosomes following starvation or iron depletion (PubMed:25327288). Ensures efficient erythropoiesis, possibly by regulating he

LOCALIZAÇÃO

Cytoplasmic vesicle, autophagosomeAutolysosomeNucleusChromosome

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
122.0 TPM
Fibroblastos
117.3 TPM
Artéria tibial
110.7 TPM
Bladder
108.6 TPM
Esôfago - Muscular
102.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:7671UniProt:Q13772
NDUFA13NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Disease-causing somatic mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis (PubMed:27626371). Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:27626371). Involved in the interferon/all-trans-retinoic acid (IFN/RA) induced cell death. This apoptotic activity is inhibited by interaction with viral IRF1. Preve

LOCALIZAÇÃO

Mitochondrion inner membraneNucleus

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Hurthle cell thyroid carcinoma

A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
261.5 TPM
Coração - Ventrículo esquerdo
190.8 TPM
Coração - Átrio
181.5 TPM
Pituitária
162.4 TPM
Brain Frontal Cortex BA9
149.7 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 28differentiated thyroid carcinomathyroid Hurthle cell carcinoma
HGNC:17194UniProt:Q9P0J0
SRGAP1SLIT-ROBO Rho GTPase-activating protein 1Candidate gene tested inAltamente restrito
FUNÇÃO

GTPase-activating protein for RhoA and Cdc42 small GTPases. Together with CDC42 seems to be involved in the pathway mediating the repulsive signaling of Robo and Slit proteins in neuronal migration. SLIT2, probably through interaction with ROBO1, increases the interaction of SRGAP1 with ROBO1 and inactivates CDC42

LOCALIZAÇÃO

VIAS BIOLÓGICAS (4)
Inactivation of CDC42 and RAC1RAC1 GTPase cycleCDC42 GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 2

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
11.4 TPM
Cervix Ectocervix
4.8 TPM
Nervo tibial
4.6 TPM
Pulmão
4.2 TPM
Cervix Endocervix
4.0 TPM
OUTRAS DOENÇAS (1)
thyroid cancer, nonmedullary, 2
HGNC:HGNC:17382UniProt:Q7Z6B7
EIF1AXEukaryotic translation initiation factor 1A, X-chromosomalDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Component of the 43S pre-initiation complex (43S PIC), which binds to the mRNA cap-proximal region, scans mRNA 5'-untranslated region, and locates the initiation codon (PubMed:9732867). This protein enhances formation of the cap-proximal complex (PubMed:9732867). Together with EIF1, facilitates scanning, start codon recognition, promotion of the assembly of 48S complex at the initiation codon (43S PIC becomes 48S PIC after the start codon is reached), and dissociation of aberrant complexes (PubM

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (6)
Translation initiation complex formationRibosomal scanning and start codon recognitionGTP hydrolysis and joining of the 60S ribosomal subunitL13a-mediated translational silencing of Ceruloplasmin expressionFormation of the ternary complex, and subsequently, the 43S complex
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
82.9 TPM
Ovário
72.0 TPM
Útero
71.4 TPM
Cervix Ectocervix
60.4 TPM
Fallopian Tube
60.4 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:3250UniProt:P47813
TRIM27Zinc finger protein RFPPart of a fusion gene inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that mediates ubiquitination of various substrates and thereby plays a role in diffent processes including proliferation, innate immunity, apoptosis, immune response or autophagy (PubMed:22829933, PubMed:24144979, PubMed:29688809, PubMed:36111389). Ubiquitinates PIK3C2B and inhibits its activity by mediating the formation of 'Lys-48'-linked polyubiquitin chains; the function inhibits CD4 T-cell activation. Acts as a regulator of retrograde transport: together with MAG

LOCALIZAÇÃO

NucleusCytoplasmNucleus, PML bodyEarly endosomeMitochondrion

VIAS BIOLÓGICAS (2)
Regulation of PTEN stability and activitySuppression of apoptosis
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
61.2 TPM
Fallopian Tube
55.1 TPM
Baço
54.4 TPM
Cervix Ectocervix
53.1 TPM
Útero
49.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:9975UniProt:P14373
GAS8-AS1Uncharacterized protein GAS8-AS1Disease-causing somatic mutation(s) inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Activation of SMO
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:1197UniProt:O95177
NTRK1High affinity nerve growth factor receptorPart of a fusion gene inTolerante
FUNÇÃO

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axon

LOCALIZAÇÃO

Cell membraneEarly endosome membraneLate endosome membraneRecycling endosome membrane

VIAS BIOLÓGICAS (1)
TRKA activation by NGF
MECANISMO DE DOENÇA

Congenital insensitivity to pain with anhidrosis

Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.

EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
5.7 TPM
Testículo
4.9 TPM
Cervix Endocervix
4.3 TPM
Útero
3.7 TPM
Fallopian Tube
3.5 TPM
OUTRAS DOENÇAS (4)
hereditary sensory and autonomic neuropathy type 4hereditary sensory and autonomic neuropathy type 5familial medullary thyroid carcinomadifferentiated thyroid carcinoma
HGNC:8031UniProt:P04629
LPAR4Lysophosphatidic acid receptor 4Disease-causing somatic mutation(s) inTolerante
FUNÇÃO

Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Transduces a signal by increasing the intracellular calcium ions and by stimulating adenylyl cyclase activity. The rank order of potency for agonists of this receptor is 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsP2Y receptors
EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
3.0 TPM
Esôfago - Junção
1.2 TPM
Útero
0.9 TPM
Cervix Endocervix
0.8 TPM
Esôfago - Muscular
0.7 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:4478UniProt:Q99677
NKX2-1Homeobox protein Nkx-2.1Major susceptibility factor inAltamente restrito
FUNÇÃO

Transcription factor that binds and activates the promoter of thyroid specific genes such as thyroglobulin, thyroperoxidase, and thyrotropin receptor. Crucial in the maintenance of the thyroid differentiation phenotype. May play a role in lung development and surfactant homeostasis. Forms a regulatory loop with GRHL2 that coordinates lung epithelial cell morphogenesis and differentiation. Activates the transcription of GNRHR and plays a role in enhancing the circadian oscillation of its gene exp

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cellsRegulation of gene expression in beta cells
MECANISMO DE DOENÇA

Chorea, hereditary benign

A rare autosomal dominant movement disorder, defined by early onset in childhood, a stable or non-progressive course of chorea, and no mental deterioration. Chorea is characterized by involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement.

EXPRESSÃO TECIDUAL(Tecido-específico)
Tireoide
352.6 TPM
Pulmão
89.7 TPM
Hipotálamo
5.6 TPM
Brain Caudate basal ganglia
3.5 TPM
Brain Nucleus accumbens basal ganglia
3.3 TPM
OUTRAS DOENÇAS (6)
brain-lung-thyroid syndromehereditary progressive chorea without dementiaathyreosisdifferentiated thyroid carcinoma
HGNC:11825UniProt:P43699
ALKALK tyrosine kinase receptorPart of a fusion gene inRestrito
FUNÇÃO

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a nega

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Signaling by ALKMDK and PTN in ALK signaling
OUTRAS DOENÇAS (9)
large congenital melanocytic nevusneuroblastomaganglioneuroblastomadifferentiated thyroid carcinoma
HGNC:427UniProt:Q9UM73
TPRNucleoprotein TPRPart of a fusion gene inAltamente restrito
FUNÇÃO

Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs, plays a role in the establishment of nuclear-peripheral chromatin compartmentalization in interphase, and in the mitotic spindle checkpoint signaling during mitosis. Involved in the quality control and retention of unspliced mRNAs in the nucleus; i

LOCALIZAÇÃO

NucleusNucleus membraneNucleus envelopeNucleus, nuclear pore complexCytoplasmCytoplasm, cytoskeleton, spindleChromosome, centromere, kinetochore

VIAS BIOLÓGICAS (10)
snRNP AssemblyHCMV Early EventsHCMV Late EventsNEP/NS2 Interacts with the Cellular Export MachineryTransport of Ribonucleoproteins into the Host Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
75.9 TPM
Linfócitos
72.8 TPM
Fibroblastos
64.6 TPM
Tireoide
48.7 TPM
Ovário
48.7 TPM
OUTRAS DOENÇAS (3)
intellectual developmental disorder, autosomal recessive 79autosomal recessive non-syndromic intellectual disabilitydifferentiated thyroid carcinoma
HGNC:12017UniProt:P12270
PAX8Paired box protein Pax-8Part of a fusion gene inAltamente restrito
FUNÇÃO

Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (2)
Formation of the nephric ductFormation of intermediate mesoderm
MECANISMO DE DOENÇA

Hypothyroidism, congenital, non-goitrous, 2

A disease characterized by thyroid dysgenesis, the most frequent cause of congenital hypothyroidism, accounting for 85% of case. The thyroid gland can be completely absent (athyreosis), ectopically located and/or severely hypoplastic. Ectopic thyroid gland is the most frequent malformation, with thyroid tissue being found most often at the base of the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
1192.7 TPM
Rim - Medula
275.9 TPM
Rim - Córtex
170.0 TPM
Fallopian Tube
28.9 TPM
Glândula adrenal
5.5 TPM
OUTRAS DOENÇAS (5)
hypothyroidism, congenital, nongoitrous, 2thyroid hypoplasiaathyreosisdifferentiated thyroid carcinoma
HGNC:8622UniProt:Q06710
DIRC3Major susceptibility factor inDesconhecido
LOCALIZAÇÃO

OUTRAS DOENÇAS (2)
differentiated thyroid carcinomahereditary clear cell renal cell carcinoma
HGNC:17805
PCM1Pericentriolar material 1 proteinPart of a fusion gene inTolerante
FUNÇÃO

Required for centrosome assembly and function (PubMed:12403812, PubMed:15659651, PubMed:16943179). Essential for the correct localization of several centrosomal proteins including CEP250, CETN3, PCNT and NEK2 (PubMed:12403812, PubMed:15659651). Required to anchor microtubules to the centrosome (PubMed:12403812, PubMed:15659651). Also involved in cilium biogenesis by recruiting the BBSome, a ciliary protein complex involved in cilium biogenesis, to the centriolar satellites (PubMed:20551181, PubM

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasmic granuleCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satelliteCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (7)
Recruitment of mitotic centrosome proteins and complexesLoss of proteins required for interphase microtubule organization from the centrosomeLoss of Nlp from mitotic centrosomesRegulation of PLK1 Activity at G2/M TransitionAURKA Activation by TPX2
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
106.3 TPM
Linfócitos
63.2 TPM
Ovário
55.1 TPM
Cérebro - Hemisfério cerebelar
49.3 TPM
Útero
48.2 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:8727UniProt:Q15154
MINPP1Multiple inositol polyphosphate phosphatase 1Candidate gene tested inTolerante
FUNÇÃO

Multiple inositol polyphosphate phosphatase that hydrolyzes 1D-myo-inositol 1,3,4,5,6-pentakisphosphate (InsP5[2OH]) and 1D-myo-inositol hexakisphosphate (InsP6) to a range of less phosphorylated inositol phosphates. This regulates the availability of these various small molecule second messengers and metal chelators which control many aspects of cell physiology (PubMed:33257696, PubMed:36589890). Has a weak in vitro activity towards 1D-myo-inositol 1,4,5-trisphosphate which is unlikely to be ph

LOCALIZAÇÃO

Endoplasmic reticulum lumenSecretedCell membrane

VIAS BIOLÓGICAS (1)
Synthesis of IPs in the ER lumen
MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 2

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
34.1 TPM
Glândula adrenal
24.9 TPM
Ovário
14.8 TPM
Linfócitos
14.0 TPM
Pulmão
13.4 TPM
OUTRAS DOENÇAS (4)
pontocerebellar hypoplasia, type 16familial papillary or follicular thyroid carcinomapontocerebellar hypoplasia type 7thyroid cancer, nonmedullary, 2
HGNC:7102UniProt:Q9UNW1
KRASGTPase KRasDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
TERTTelomerase reverse transcriptaseDisease-causing somatic mutation(s) inRestrito
FUNÇÃO

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-de

LOCALIZAÇÃO

Nucleus, nucleolusNucleus, nucleoplasmNucleusChromosome, telomereCytoplasmNucleus, PML body

VIAS BIOLÓGICAS (3)
Telomere Extension By TelomeraseFormation of the beta-catenin:TCF transactivating complexRegulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
2.7 TPM
Intestino delgado
0.7 TPM
Brain Caudate basal ganglia
0.6 TPM
Cólon transverso
0.5 TPM
Brain Nucleus accumbens basal ganglia
0.5 TPM
OUTRAS DOENÇAS (13)
dyskeratosis congenita, autosomal dominant 2pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1adrenal cortex carcinomaclear cell sarcoma of kidney
HGNC:11730UniProt:O14746
HABP2Factor VII-activating proteaseCandidate gene tested inTolerante
FUNÇÃO

Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and does not cause the fibrinolysis directly (PubMed:11217080). It does not cleave (activate) prothrombin and plasminogen but converts the inactive single chain urinary plasminogen activator (pro-urokinase) to the active two chain form (PubMed:10754382, PubMed:11217080). Activates coagulation factor VII (

LOCALIZAÇÃO

Secreted

MECANISMO DE DOENÇA

Thyroid cancer, non-medullary, 5

A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
120.6 TPM
Rim - Córtex
8.6 TPM
Pâncreas
6.3 TPM
Rim - Medula
3.6 TPM
Estômago
2.3 TPM
OUTRAS DOENÇAS (3)
familial papillary or follicular thyroid carcinomathrombophilia due to thrombin defectthyroid cancer, nonmedullary, 5
HGNC:4798UniProt:Q14520
RETProto-oncogene tyrosine-protein kinase receptor RetPart of a fusion gene inAltamente restrito
FUNÇÃO

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not onl

LOCALIZAÇÃO

Cell membraneEndosome membrane

VIAS BIOLÓGICAS (4)
RET signalingFormation of the ureteric budFormation of the nephric ductNPAS4 regulates expression of target genes
MECANISMO DE DOENÇA

Hirschsprung disease 1

A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
6.3 TPM
Pituitária
4.8 TPM
Cerebelo
4.0 TPM
Cólon sigmoide
4.0 TPM
Brain Frontal Cortex BA9
3.8 TPM
OUTRAS DOENÇAS (12)
multiple endocrine neoplasia type 2Bpheochromocytomafamilial medullary thyroid carcinomamultiple endocrine neoplasia type 2A
HGNC:9967UniProt:P07949
CCDC6Coiled-coil domain-containing protein 6Part of a fusion gene inAltamente restrito
LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Signaling by FGFR2 fusions
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:18782UniProt:Q16204
ETV6Transcription factor ETV6Part of a fusion gene inAltamente restrito
FUNÇÃO

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Signaling by FLT3 fusion proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
45.0 TPM
Glândula salivar
42.7 TPM
Skin Sun Exposed Lower leg
35.5 TPM
Linfócitos
30.0 TPM
Aorta
29.4 TPM
OUTRAS DOENÇAS (9)
acute myeloid leukemiathrombocytopenia 5B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)obsolete autosomal thrombocytopenia with normal platelets
HGNC:3495UniProt:P41212
NRASGTPase NRasDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsNeutrophil degranulation
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
77.3 TPM
Fibroblastos
52.5 TPM
Skin Not Sun Exposed Suprapubic
25.1 TPM
Esôfago - Mucosa
24.4 TPM
Skin Sun Exposed Lower leg
23.4 TPM
OUTRAS DOENÇAS (13)
neurocutaneous melanocytosislarge congenital melanocytic nevusthyroid cancer, nonmedullary, 2colorectal cancer
HGNC:7989UniProt:P01111
ESR2Estrogen receptor betaCandidate gene tested inTolerante
FUNÇÃO

Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerExtra-nuclear estrogen signaling
MECANISMO DE DOENÇA

Ovarian dysgenesis 8

An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
4.6 TPM
Testículo
3.9 TPM
Glândula adrenal
3.6 TPM
Linfócitos
2.3 TPM
Cervix Endocervix
1.4 TPM
OUTRAS DOENÇAS (2)
ovarian dysgenesis 8familial medullary thyroid carcinoma
HGNC:3468UniProt:Q92731
TFGProtein TFGPart of a fusion gene inModerado
FUNÇÃO

Plays a role in the normal dynamic function of the endoplasmic reticulum (ER) and its associated microtubules (PubMed:23479643, PubMed:27813252). Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus (PubMed:21478858)

LOCALIZAÇÃO

Endoplasmic reticulum

VIAS BIOLÓGICAS (1)
COPII-mediated vesicle transport
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
86.6 TPM
Linfócitos
61.6 TPM
Tireoide
60.1 TPM
Nervo tibial
55.3 TPM
Aorta
53.8 TPM
OUTRAS DOENÇAS (5)
hereditary motor and sensory neuropathy, Okinawa typehereditary spastic paraplegia 57autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutationdifferentiated thyroid carcinoma
HGNC:11758UniProt:Q92734
NTRK3NT-3 growth factor receptorPart of a fusion gene inAltamente restrito
FUNÇÃO

Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (4)
NTF3 activates NTRK3 signalingSignaling by NTRK3 (TRKC)NTRK3 as a dependence receptorReceptor-type tyrosine-protein phosphatases
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
32.5 TPM
Artéria coronária
22.1 TPM
Aorta
21.6 TPM
Cerebelo
15.8 TPM
Cérebro - Hemisfério cerebelar
13.9 TPM
OUTRAS DOENÇAS (3)
congenital mesoblastic nephromadifferentiated thyroid carcinomafibrosarcoma
HGNC:8033UniProt:Q16288
PPARGPeroxisome proliferator-activated receptor gammaPart of a fusion gene inModerado
FUNÇÃO

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metab

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (7)
Regulation of PTEN gene transcriptionTranscriptional regulation of white adipocyte differentiationPPARA activates gene expressionMECP2 regulates transcription factorsNuclear Receptor transcription pathway
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
111.2 TPM
Adipose Visceral Omentum
100.8 TPM
Mama
71.3 TPM
Cólon transverso
21.6 TPM
Fibroblastos
20.4 TPM
OUTRAS DOENÇAS (6)
type 2 diabetes mellitusPPARG-related familial partial lipodystrophyinherited obesitygliosarcoma
HGNC:9236UniProt:P37231
FOXE1Forkhead box protein E1Major susceptibility factor inTolerante
FUNÇÃO

Transcription factor that binds consensus sites on a variety of gene promoters and activate their transcription. Involved in proper palate formation, most probably through the expression of MSX1 and TGFB3 genes which are direct targets of this transcription factor. Also implicated in thyroid gland morphogenesis. May indirectly play a role in cell growth and migration through the regulation of WNT5A expression

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Bamforth-Lazarus syndrome

An autosomal recessive disease characterized by congenital hypothyroidism due to thyroid agenesis or thyroid hypoplasia, cleft palate, spiky hair, with or without choanal atresia, and bifid epiglottis.

EXPRESSÃO TECIDUAL(Tecido-específico)
Tireoide
164.5 TPM
Esôfago - Mucosa
8.2 TPM
Vagina
6.1 TPM
Testículo
1.1 TPM
Skin Not Sun Exposed Suprapubic
1.0 TPM
OUTRAS DOENÇAS (5)
Bamforth-Lazarus syndromedifferentiated thyroid carcinomafamilial papillary or follicular thyroid carcinomaathyreosis
HGNC:3806UniProt:O00358
BRAFSerine/threonine-protein kinase B-rafDisease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
ERC1ELKS/Rab6-interacting/CAST family member 1Part of a fusion gene inRestrito
FUNÇÃO

Regulatory subunit of the IKK complex. Probably recruits IkappaBalpha/NFKBIA to the complex. May be involved in the organization of the cytomatrix at the nerve terminals active zone (CAZ) which regulates neurotransmitter release. May be involved in vesicle trafficking at the CAZ. May be involved in Rab-6 regulated endosomes to Golgi transport

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasmMembraneGolgi apparatus membranePresynaptic cell membraneCell projection, podosome

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
34.8 TPM
Cerebelo
32.7 TPM
Artéria tibial
25.6 TPM
Aorta
21.0 TPM
Esôfago - Muscular
20.6 TPM
OUTRAS DOENÇAS (2)
distal monosomy 12pdifferentiated thyroid carcinoma
HGNC:17072UniProt:Q8IUD2
GOLGA5Golgin subfamily A member 5Part of a fusion gene inTolerante
FUNÇÃO

Involved in maintaining Golgi structure. Stimulates the formation of Golgi stacks and ribbons. Involved in intra-Golgi retrograde transport

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Intra-Golgi traffic
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
80.9 TPM
Testículo
55.1 TPM
Artéria tibial
49.1 TPM
Aorta
47.0 TPM
Tecido adiposo
45.9 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:4428UniProt:Q8TBA6
TRIM24Transcription intermediary factor 1-alphaPart of a fusion gene inAltamente restrito
FUNÇÃO

Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. During the DNA damage response, participates in an autoregulatory feedback loop with TP53. Early in response to DNA damage, ATM

LOCALIZAÇÃO

NucleusCytoplasmMitochondrion

VIAS BIOLÓGICAS (2)
Signaling by FGFR1 in diseaseSignaling by cytosolic FGFR1 fusion mutants
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
20.9 TPM
Glândula adrenal
19.9 TPM
Ovário
16.5 TPM
Linfócitos
9.1 TPM
Próstata
7.9 TPM
OUTRAS DOENÇAS (1)
differentiated thyroid carcinoma
HGNC:11812UniProt:O15164

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 sorafenib (SORAFENIB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

225 variantes patogênicas registradas no ClinVar.

🧬 HRAS: GRCh38/hg38 11p15.5-15.4(chr11:198510-3400939)x3 ()
🧬 HRAS: NM_005343.4(HRAS):c.269T>G (p.Phe90Cys) ()
🧬 HRAS: NM_005343.4(HRAS):c.217_218insCGGCCAGCGCCATGCGGGACCAGTACATGC (p.Met72_Arg73insProAlaSerAlaMetArgAspGlnTyrMet) ()
🧬 HRAS: NM_005343.4(HRAS):c.174_179delinsATCTGGATACAT (p.Ala59_Gly60delinsSerGlyTyrIle) ()
🧬 HRAS: NM_005343.4(HRAS):c.204_218dup (p.Arg73_Thr74insAspGlnTyrMetArg) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

174 vias biológicas associadas aos genes desta condição.

SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling Downregulation of SMAD2/3:SMAD4 transcriptional activity Germ layer formation at gastrulation Coactivators are recruited to liganded PPARG:RXRA heterodimer Respiratory electron transport Complex I biogenesis Mitochondrial protein degradation Inactivation of CDC42 and RAC1 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle L13a-mediated translational silencing of Ceruloplasmin expression Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit SUMOylation of ubiquitinylation proteins Regulation of PTEN stability and activity Suppression of apoptosis GAS8 GATA6-AS1 lncRNA p-2S-SMAD2,3:GATA6-AS1 lncRNA:GATA6 gene AS160:IRAP Phospho AS160:14-3-3 p-5S,T642-AS160:IRAP p-5S,T642-AS160:14-3-3:IRAP SMAD2,3 and GATA6-AS1 lncRNA bind the GATA6 gene 14-3-3 binds p-5S,T642-AS160 (TBC1D4) p-AKT1,p-AKT2 phosphorylates AS160 (TBC1D4) CTBP1,CTBP2 binds ZEB1 CD274 mRNA binds miR-142-5p RISC Expression of GATA6 in definitive endoderm CTBP1,CTBP2 binds CDH1 gene promoter SMO translocates to the cilium PLC-gamma1 signalling Frs2-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation Signalling to STAT3 G alpha (q) signalling events P2Y receptors Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells Cardiogenesis Signaling by ALK ALK mutants bind TKIs ASP-3026-resistant ALK mutants NVP-TAE684-resistant ALK mutants alectinib-resistant ALK mutants brigatinib-resistant ALK mutants ceritinib-resistant ALK mutants crizotinib-resistant ALK mutants lorlatinib-resistant ALK mutants Signaling by ALK fusions and activated point mutants MDK and PTN in ALK signaling ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA Derived from an Intronless Transcript Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs snRNP Assembly SUMOylation of DNA damage response and repair proteins Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Early Events HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Formation of intermediate mesoderm Formation of the nephric duct Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane AURKA Activation by TPX2 Synthesis of IPs in the ER lumen Ca2+ pathway Telomere Extension By Telomerase Formation of the beta-catenin:TCF transactivating complex Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence RAF/MAP kinase cascade RET signaling NPAS4 regulates expression of target genes Formation of the ureteric bud Signaling by FGFR2 fusions Signaling by membrane-tethered fusions of PDGFRA or PDGFRB Signaling by FLT3 fusion proteins SHC-mediated cascade:FGFR4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling COPII-mediated vesicle transport Receptor-type tyrosine-protein phosphatases NTF3 activates NTRK3 signaling Signaling by NTRK3 (TRKC) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through RAS Activated NTRK3 signals through PI3K NTRK3 as a dependence receptor PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation SUMOylation of intracellular receptors Regulation of PTEN gene transcription MECP2 regulates transcription factors MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 TSHR binds TSH/Thyrostimulin Spry regulation of FGF signaling RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling Intra-Golgi traffic Signaling by cytosolic FGFR1 fusion mutants Signaling by FGFR1 in disease

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 28
1Fase 13
·Pré-clínico8
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Carcinoma da tireoide diferenciado

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

15 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

207 ensaios clínicos encontrados, 35 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
1.990 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.990

#1

The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.

Cell death discovery2026 Feb 25

One of the fastest-growing malignant tumors in the world is thyroid cancer (TC), and there are currently no effective treatments for its aggressive subtypes, such as anaplastic carcinoma and radioactive iodine-refractory differentiated thyroid carcinoma. Recent investigations have shown that DNA methylation and metabolic reprogramming are not independent events, but rather create a closely interconnected, mutually reinforcing network of carcinogenic processes. On the one hand, metabolic reprogramming influences the methylation status of tumor suppressor genes and thyroid function genes by dynamically regulating the activity of DNA methyltransferases and demethylases through important metabolites (such as S-adenosylmethionine, or SAM, and α-KG) and oncogenic signaling pathways (like PI3K/AKT). Conversely, DNA methylation systematically remodels cellular glucose, lipid, and amino acid metabolism by directly silencing metabolic enzyme genes (such as FASN and GLS) and thyroid differentiation markers (such as NIS) to fulfill its proliferative demands. Tumor growth, treatment resistance, and the development of an immunosuppressive microenvironment are all fueled by this ongoing bidirectional interaction, which creates a self-reinforcing oncogenic cycle. As a result, the limitations of earlier discrete debates on DNA methylation or metabolic reprogramming are overcome in this review. To methodically clarify their crosstalk mechanisms, a theoretical framework based on the "DNA methylation-metabolism axis" is suggested. Additionally, it suggests multimodal therapy approaches that focus on this axis. Incorporating biomimetic delivery technologies, combined with epigenetic, metabolic, and immunotherapies, to lay the groundwork for comprehending TC causes and creating targeted treatments.

#2

The Role of 123I in the Management of Differentiated Thyroid Cancer: A Comprehensive Narrative Review.

Medical sciences (Basel, Switzerland)2026 Feb 02

Differentiated thyroid carcinoma (DTC) is the most common malignant endocrine tumor, with a generally favorable prognosis. Imaging, including iodine radioactive isotope scintigraphy (IRIS), is crucial for diagnosis and follow-up. While 131I has long been used for both therapeutic and diagnostic purposes, 123I is reserved for diagnostic imaging due to its shorter half-life and γ emissions. This review highlights the utility of 123I scintigraphy, especially in pre-treatment assessment and dosimetry for DTC. It is particularly valuable before radioiodine (RAI) ablation, providing accurate imaging in patients with iodine-refractory (IR) or biochemically incomplete response (BIR) DTC. When compared to post-therapeutic 131I scans, 123I scintigraphy appears to have a lower sensitivity for detecting metastatic lesions, particularly in lymph nodes and lungs. However, its diagnostic performance compared to low-dose diagnostic 131I is more variable, with some studies suggesting superiority due to the absence of stunning. Further research is needed to standardize its use and optimize its role in guiding DTC management.

#3

Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer.

Molecular &amp; cellular proteomics : MCP2026 Jan 19

Thyroid cancer comprises a heterogeneous group of malignancies with distinct clinical outcomes and molecular features, including papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). This study aimed to delineate the molecular and immune landscapes of these subtypes and identify potential biomarkers for the aggressive forms, ATC and PDTC. We assembled a well-annotated cohort of 120 formalin-fixed paraffin-embedded samples, including 35 ATC, 18 PDTC, 37 PTC cases, and 30 adjacent normal tissues (N) paired with PTC, collected over the past decade from multiple hospitals. To our knowledge, this represents the largest clinical ATC/PDTC cohort subjected to multiomics profiling and the first comprehensive proteomic analysis of these aggressive thyroid cancers. Using 4D-data-independent acquisition proteomics on 118 tumors (ATC 34, PDTC 18, PTC 36, and N 30), integrated with total RNA-seq on 69 samples (ATC 10, PDTC 5, PTC 31, and N 23), we revealed substantial molecular similarities between ATC and PDTC, both markedly distinct from PTC and adjacent normal tissues. ATC and PDTC exhibited significant enrichment in immune-related and metabolic pathways, with transcriptomic data indicating aggressive phenotypes and pronounced immunosuppression. Distinct immune landscapes of ATC and PDTC were revealed with neutrophil extracellular trap formation and M0 macrophage accumulation as key immunosuppressive mechanisms. Notably, Fc fragment of IgG receptor IIa (CD32) was identified as a promising biomarker for ATC, implicating a functional link between immune evasion and tumor aggressiveness. Our findings provide a comprehensive molecular and immunological characterization of thyroid cancer subtypes, offering novel insights into the pathogenesis of ATC and PDTC, and identifying potential targets for diagnosis and precision therapy.

#4

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Frontiers in oncology2026

ALK rearrangements are rare but actionable oncogenic drivers in thyroid cancer, particularly in aggressive histologies such as poorly differentiated thyroid carcinoma (PDTC), and evidence supporting sequential ALK inhibition in this setting is scarce. We report a 19-year-old male with ALK-rearranged, radioiodine-refractory PDTC who started systemic therapy with ceritinib, achieving a complete metabolic response. After treatment discontinuation and subsequent progression despite ceritinib reintroduction, lorlatinib was initiated. Treatment with the third-generation ALK inhibitor led to a deep and durable complete metabolic response, sustained for more than four years, including persistence of remission after treatment discontinuation, with minimal toxicity. This case highlights the potential role of sequential ALK inhibition to overcome acquired resistance in ALK-rearranged TC and underscores the importance of comprehensive molecular profiling to guide personalized treatment strategies in rare aggressive thyroid cancers.

#5

ARISK STRATIFICATION AND LONG-TERM MONITORING IN PEDIATRIC THYROID CANCER: PREDICTIVE MARKERS FOR DISEASE PERSISTENCE.

European thyroid journal2026 Mar 13

Initial and dynamic risk stratification are crucial in managing pediatric differentiated thyroid carcinoma (DTC), aiming to guide treatment and long-term follow-up. While adult dynamic stratification is well established, pediatric data remain limited, and no formal recommendations exist for its use. To evaluate the prognostic value of early dynamic risk stratification (EDRS) and postoperative stimulated thyroglobulin (sPOTg) in predicting long-term outcomes in pediatric DTC and to compare EDRS with initial ATA pediatric risk stratification (IRS). We conducted a retrospective cohort study of 123 patients ≤18 years with DTC treated at a tertiary center. IRS and EDRS (1-3 years post-treatment) were compared to late dynamic response (LDRS, ≥10 years post-treatment). A total of 83 patients had complete long-term follow-up data. Associations were assessed using chi-square tests, logistic regression, Cohen's Kappa, and Cramér's V. ROC curve analysis evaluated the predictive value of sPOTg. Among 83 patients with ≥10 years of follow-up, EDRS showed a strong association with LDRS (Cramér's V = 0.829; p < 0.001), outperforming IRS (Cramér's V = 0.33; p = 0.0029). Concordance between EDRS and LDRS was substantial (Kappa = 0.79). Stimulated Postoperative Thyroglobulin (sPOTg) showed good discriminatory performance for disease persistence, with AUCs of 0.84 (95% CI: 0.70-0.95) at 1-3 years and 0.81 at ≥10 years. Early dynamic response is a strong predictor of long-term outcomes and may surpass IRS in prognostic accuracy. sPOTg is a valuable biomarker for both early and late risk assessment. Prospective multicenter validation is warranted.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.145 artigos no totalmostrando 199

2026

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Frontiers in oncology
2026

ARISK STRATIFICATION AND LONG-TERM MONITORING IN PEDIATRIC THYROID CANCER: PREDICTIVE MARKERS FOR DISEASE PERSISTENCE.

European thyroid journal
2026

Epidemiology, risk factor and prognostic factor of young differentiated thyroid carcinoma with distant metastasis: a retrospective cohort study.

American journal of cancer research
2026

Status of therapeutic nuclear medicine in Argentina.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
2026

Sex-specific differences in patients with differentiated thyroid carcinoma and their possible impact on survival.

European journal of nuclear medicine and molecular imaging
2026

Prognostic significance of minimal extrathyroidal extension in differentiated thyroid carcinoma: a retrospective cohort study.

Brazilian journal of otorhinolaryngology
2026

Selective Use of Radioiodine Therapy in Differentiated Thyroid Carcinoma: A Population-Based Cohort Study.

Thyroid : official journal of the American Thyroid Association
2026

Simulation unlocked: transforming thyroid surgery training through high-fidelity and curriculum-based innovation-a systematic review.

Langenbeck's archives of surgery
2026

Thyroglobulin Autoantibodies Do Not Influence the Outcome of Patients With Differentiated Thyroid Carcinoma.

Endocrinology, diabetes &amp; metabolism
2026

CYFRA 21-1 in lymph node fine-needle aspiration washouts: added value in differentiated thyroid cancer.

Clinical chemistry and laboratory medicine
2026

Fgfr4 combined with inflammatory cytokines improves recurrence risk prediction in differentiated thyroid carcinoma: A retrospective cohort study.

Journal of medical biochemistry
2026

[Current status and controversies of thyroid stimulating hormone suppression therapy in low-risk differentiated thyroid carcinoma].

Zhonghua yi xue za zhi
2026

Fibrosis-Driven Surgical Risk After Thyroid Nodule Ablation: Quantitative Clinicopathological Determinants of Complications in Post-Ablative Thyroidectomy-A Retrospective Cohort Study.

World journal of surgery
2026

Lenvatinib as Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: CT-Based Selection and Outcomes From a 23-Patient Cohort.

Head &amp; neck
2026

Differences in laboratory reporting of thyroglobulin antibody positivity - a national survey across laboratories in the Netherlands.

Clinical chemistry and laboratory medicine
2026

Sexual Function and Depressive Symptoms in Premenopausal Women with Differentiated Thyroid Cancer: A Cross-Sectional Study.

Thyroid : official journal of the American Thyroid Association
2026

Visualizing malignant progression: in situ CD109-based spatial immunofluorescence assay delineates papillary to anaplastic thyroid carcinoma transformation within the tumor microenvironment.

Scientific reports
2026

Evaluation of three inflammation-associated blood indices for predicting malignancy in thyroid nodules.

Archives of endocrinology and metabolism
2026

The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.

Cell death discovery
2026

Training pathways and formal curricula in robotic bariatric surgery: a systematic review.

Journal of robotic surgery
2026

Prognostic significance of preoperative thyroid hormone sensitivity status for recurrence in papillary thyroid carcinoma.

The oncologist
2026

Pre-RAI Monocyte-to-Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate-Risk DTC, While PNI and NRI Show No Prognostic Value.

Clinical endocrinology
2026

The Role of 123I in the Management of Differentiated Thyroid Cancer: A Comprehensive Narrative Review.

Medical sciences (Basel, Switzerland)
2026

Comparable survival after lobectomy and total thyroidectomy for T3b differentiated thyroid carcinoma: A population-based study.

Oral oncology
2026

Comparative evaluation of dynamic risk stratification according to ATA 2015 and ATA 2025 in low-risk differentiated thyroid cancer without radioiodine ablation.

Endocrine
2026

Case Report: Management of a challenging case presenting with dysphagia after thyroidectomy requiring administration of liquid 131I via MIC-KEY low-profile tube-a multidisciplinary approach.

Frontiers in medicine
2026

Outside canonical BRAF p.V600E Box: 7 novel BRAF gene fusions in BRAF p.V600E WT papillary thyroid carcinoma.

Virchows Archiv : an international journal of pathology
2026

Clinical characteristics and risk analysis of lymph node metastasis in patients with cN0 differentiated thyroid carcinoma.

Scientific reports
2026

Construction and evaluation of a SPECT-based radiomics nomogram for predicting the therapeutic response to radioactive iodine in patients with differentiated thyroid carcinoma.

Medicine
2026

Reconstruction of the chest wall after resection of a locally advanced poorly differentiated thyroid carcinoma with sternal infiltration: case report and literature review.

AME case reports
2026

Implantation of cancer cells from transoral endoscopic thyroidectomy: a case report.

Gland surgery
2026

Synchronous Presence of Papillary, Medullary, and Anaplastic Thyroid Tumors in a Single Patient: A Rare Case Report.

The American journal of case reports
2026

Prognostic Stratification of Highly Differentiated Thyroid Cancer Based on Molecular Genetic Studies.

Asian Pacific journal of cancer prevention : APJCP
2026

Thyroid carcinoma follow-up: tertiary to primary care transition in Portugal.

Endocrine connections
2026

Analysis of external dose rate attenuation and its related factors in differentiated thyroid carcinoma patients following I-131 therapy.

EJNMMI physics
2026

Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects.

The oncologist
2026

Immunotherapy response in microsatellite-stable poorly differentiated thyroid carcinoma with mismatch repair deficiency and high tumor mutational burden.

Archives of endocrinology and metabolism
2026

A Case of Thyroid Carcinoma Combined With Thyroid Hemiagenesis.

Case reports in endocrinology
2026

[Differentiated thyroid carcinoma in children and adolescents].

Problemy endokrinologii
2026

Effects of High-dose Radioactive Iodine Therapy on Hormonal Profiles and Sperm Quality in Thyroidectomy Patients.

Molecular imaging and radionuclide therapy
2026

Patterns of radioiodine uptake combined with pulmonary nodule size in predicting long-term clinical outcomes of differentiated thyroid carcinoma patients with lung metastasis alone.

Asia Oceania journal of nuclear medicine &amp; biology
2026

A Randomized Trial Evaluating Intraoperative Ischemic Preconditioning of Parathyroid Glands During Total Thyroidectomy: A Signal for Earlier Parathyroid Function Recovery.

Journal of investigative surgery : the official journal of the Academy of Surgical Research
2026

TERT promoter mutations and recurrence patterns in differentiated thyroid carcinoma.

Endocrine-related cancer
2026

Clinical comparative analysis of endoscopic thyroidectomy via the thoracoareolar approach versus open surgery for the treatment of differentiated thyroid cancer.

Medicine
2026

Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.

Annals of nuclear medicine
2026

Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer.

Molecular &amp; cellular proteomics : MCP
2026

Challenging Subtypes and Mimics of Papillary Thyroid Carcinoma: Highlights from a 22nd International Congress of Cytology Slide Seminar (Case Reports).

Acta cytologica
2025

Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.

Frontiers in endocrinology
2026

Head-to-Head Comparison of [68Ga]Ga-DOTATATE PET/CT and [68Ga]Ga-NODAGA-LM3 PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2026

Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.

Endocrine-related cancer
2026

Complete resection of solitary pulmonary metastases in thyroid cancer: a case series report.

Journal of cardiothoracic surgery
2026

Linoleic acid reduces sodium-iodide symporter by inhibiting endoplasmic reticulum stress in papillary thyroid carcinoma.

Journal of molecular endocrinology
2026

Solitary Flat Bone Metastasis of Follicular Thyroid Carcinoma: Complete Molecular and Partial Structural Response After 2 131I Therapies.

Journal of nuclear medicine technology
2026

Persistent and Recurrent Differentiated Thyroid Cancer: A Surgical Perspective on Overdiagnosis.

The Journal of craniofacial surgery
2026

The influence of age-independent somatic driver alterations on clinical outcomes in paediatric and young adult thyroid cancer.

European thyroid journal
2026

Machine learning prediction of thyroid cancer recurrence for early screening and clinical decision pathways: a retrospective cohort study.

Discover oncology
2026

Poorly differentiated thyroid carcinoma in identical twins: a report of two cases and review of the literature.

Thyroid research
2026

Selected updates in thyroid, parathyroid, and adrenal gland pathology.

Human pathology
2026

An integrated single-cell and spatial transcriptomic atlas of thyroid cancer progression identifies prognostic fibroblast subpopulations.

JCI insight
2025

Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma.

Frontiers in endocrinology
2025

Understanding the Factors That Influence Shared-Decision Making Around Surgical Resection of Low-Risk Thyroid Cancers: A Prospective Qualitative Study.

Thyroid : official journal of the American Thyroid Association
2025

Accuracy and Clinical Significance of Intraoperative Gross Extrathyroidal Extension (T3b) Assessment in Differentiated Thyroid Carcinoma.

Cancers
2025

Assessment of levothyroxine therapy adequacy in low-risk differentiated thyroid carcinoma: a multicenter cohort study.

Frontiers in endocrinology
2025

Revisiting Thyroglobulin Measurement: Current Methods and Future Perspectives Using Dried Blood Spot Sampling for Enhanced Clinical Practice.

Metabolites
2025

Surgical Management of Poorly Differentiated Thyroid Carcinoma Extending Into the Superior Vena Cava: A Case Report.

Cureus
2025

[Treatment outcomes and prognostic analysis of 882 cases of poorly differentiated/anaplastic thyroid carcinoma in China: a multicenter study].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2025

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi-Center Retrospective Cohort.

Head &amp; neck
2025

Levothyroxine suppression therapy improves maternal and neonatal outcomes in pregnancy after thyroidectomy for differentiated thyroid carcinoma.

American journal of translational research
2026

Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2026

Prognostic factors evaluated in differentiated thyroid carcinomas.

Endocrine connections
2025

Predictive value of serum thyroglobulin after surgery and prior to I-131 therapy in patients with differentiated thyroid carcinoma, examined at two different time intervals.

Caspian journal of internal medicine
2025

Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2025

Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma.

Endocrinology and metabolism (Seoul, Korea)
2026

Integrating Robotic Bilateral Axillo-Breast Approach Thyroidectomy with Molecular Diagnostics and Artificial Intelligence in Thyroid Cancer Care.

Biomolecules &amp; therapeutics
2025

Transoral endoscopic thyroidectomy using the vestibular approach in pediatric patients: 5-year experience in a single center in Vietnam.

World journal of pediatric surgery
2025

Comparison of surgical trauma between three endoscopic thyroidectomy approaches and open surgery.

Frontiers in oncology
2026

Prognostic Factors Affecting Iodine-131 Treatment Efficacy in Patients With Differentiated Thyroid Carcinoma: A Risk-Stratified Analysis.

Nutrition and cancer
2025

Type 2 Deiodinase in Cancer-Associated Fibroblasts is Required to Sustain Growth of Poorly and Undifferentiated Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association
2025

Age-dependent effects of surgical approach in T3b differentiated thyroid carcinoma: a population-based analysis using machine learning.

Endocrine-related cancer
2025

Long-Term Disease Control With Lenvatinib in Metastatic Malignant Struma Ovarii: A Case Report.

Cureus
2026

Extensive Intravenous Tumor Thrombus and Right Atrial Bland Thrombus From Poorly Differentiated Thyroid Cancer: 18 F-FDG PET/CT Imaging Findings.

Clinical nuclear medicine
2025

Emerging frontiers in SERS-integrated optical waveguides: advancing portable and ultra-sensitive detection for trace liquid analysis.

Light, science &amp; applications
2025

Post-thyroidectomy ultrasonography versus thyroglobulin as a surveillance tool for locoregional recurrence in patients with differentiated thyroid carcinoma: A single centre 10-year study.

Frontiers in endocrinology
2025

International Consensus on the Requirements for Definitions of Complete Remission and Recurrence of Differentiated Thyroid Cancer: a Delphi Study (ICON-DTC).

European journal of endocrinology
2025

Parity as a Risk Factor for Differentiated Thyroid Carcinoma- A Population-Based Study.

The Journal of clinical endocrinology and metabolism
2025

Rare Presentation of Mandibular Metastases from Differentiated Thyroid Carcinoma: A Case Series - Experience from a Single Tertiary Care Hospital.

Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
2026

A Randomized Controlled Trial to Evaluate the Effects of Topical Intraoperative Corticosteroid Application on Voice Quality in Thyroid Surgery With Preserved Recurrent Laryngeal Nerves.

World journal of surgery
2026

Post-therapy I-131 whole-body scan with SPECT/computed tomography-based mapping of residual metastatic lymph nodes in differentiated thyroid cancer.

Nuclear medicine communications
2025

Gut microbiota and metabolite profiles in thyroid cancer lymph node metastasis: a multi-omics analysis.

Scientific reports
2026

Novel carbon paper-based solid-state nanochannels integrated with click chemistry for sensitive detection of thyroid stimulating hormone.

Biosensors &amp; bioelectronics
2025

Prognostic analysis of persistent disease in medium-to high-risk children and adolescents with differentiated thyroid carcinoma.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Multimodal ultrasound to predict central cervical lymph node metastasis in clinically lymph node-negative differentiated thyroid carcinomas: a two-center retrospective study.

Gland surgery
2026

Unusual Soft Tissue and Muscle Metastases in Papillary Thyroid Carcinoma: Insights from 131I Scintigraphy and 18F-FDG PET/CT.

Molecular imaging and radionuclide therapy
2025

Core Outcome Set of the Surgical Treatment of Differentiated Thyroid Carcinoma: International Consensus by Delphi Study.

Thyroid : official journal of the American Thyroid Association
2026

In medio stat virtus: towards an evidence rather than dogma based discussion on indicating post-operative I-131 therapy for differentiated thyroid carcinoma.

European journal of nuclear medicine and molecular imaging
2025

Towards harmonised paediatric thyroid cancer care: adult comparisons and gaps.

Endocrine-related cancer
2026

Surgical Outcomes Following Neoadjuvant-Targeted Therapy for Advanced Differentiated Thyroid Cancer-Real-World Data.

Clinical endocrinology
2025

Dynamic risk stratification in patients with follicular thyroid carcinoma treated with lobectomy.

European thyroid journal
2025

Prognosis of differentiated thyroid cancer in patients with Graves' disease: a meta-analysis.

Thyroid research
2025

A rare case of isolated metastatic disease in a young woman with papillary thyroid carcinoma and a novel method for diagnosis: illustrative case.

Journal of neurosurgery. Case lessons
2025

Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.

European thyroid journal
2025

Patterns of Lateral Lymph Node Involvement by Neck Level in cNIb Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Diagnostics (Basel, Switzerland)
2026

Learning curve and functional safety in robotic thyroidectomy via bilateral axillo-breast approach: a prospective study of 537 cases.

Surgical endoscopy
2025

A rare case of follicular thyroid carcinoma with unknown primary tumor location.

Nuclear medicine review. Central &amp; Eastern Europe
2025

Defining the role of thyroidectomy in patients with metastatic differentiated thyroid carcinoma by age groups.

American journal of surgery
2025

High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.

Endocrine pathology
2025

Expanding the Phenotypic Spectrum of Differentiated High-Grade Thyroid Carcinoma: An Extracranial Mass as the First Presentation.

Case reports in endocrinology
2025

Metastatic follicular thyroid carcinoma to the brain during pregnancy: A neurosurgical and ethical challenge.

Surgical neurology international
2025

Case of cutaneous metastasis from presumed poorly differentiated thyroid carcinoma: a case report.

Journal of medical case reports
2025

In-vitro Assessment of the Proliferation and Apoptosis of Thyroid Cancer Cells Using Valproic Acid and Retinoic Acid Alone and in Combination with Etoposide and Epirubicin.

Iranian journal of pharmaceutical research : IJPR
2026

Prognostic Value of Hematological Inflammatory Indices (PLR, NLR, SII) in Medium and High-Risk Papillary Thyroid Carcinoma: A Multicenter Cohort Study.

Clinical endocrinology
2025

Homologous Recombination in Thyroid Tumor Samples.

International journal of molecular sciences
2025

Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.

Diagnostics (Basel, Switzerland)
2026

Radioactive iodine and male reproductive health in thyroid cancer survivors: evidence of delayed gonadal dysfunction.

Journal of endocrinological investigation
2025

Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas.

Cells
2025

Malignant Potential of Thyroid Follicular Nodular Disease With Solid/Trabecular Components: A Case Report.

Pathology international
2025

Lenvatinib-Induced Glomerular Microangiopathy in a Patient With Poorly Differentiated Thyroid Carcinoma: A Long-Term Renal Function Change With Biopsy Findings.

Cureus
2025

Clinical value of 99mTc-MIBI scintigraphy combined with posttherapeutic 131I whole-body scanning in patients with differentiated thyroid cancer with sTg ≥10 ng/mL before initial radioiodine therapy: a retrospective study.

Quantitative imaging in medicine and surgery
2025

Primary squamous thyroid cancer: A case report.

Oncology letters
2025

Radioactive iodine for differentiated thyroid carcinoma.

Current opinion in endocrinology, diabetes, and obesity
2026

Ultrasound-Guided Optimization of Preoperative Chemoradiotherapy Using ¹³¹I SPECT/CT for Enhanced Targeting in Differentiated Thyroid Carcinoma.

Cancer biotherapy &amp; radiopharmaceuticals
2025

A previously unreported triad of poorly differentiated thyroid carcinoma, parathyroid adenoma, and paraganglioma: random coincidence or hidden genetic etiology-a case report.

Journal of medical case reports
2025

Implementation of a comprehensive medication management service for radioiodine therapy patients at an oncology hospital in Rio de Janeiro.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2025

Environmental and lifestyle factors and risk of thyroid carcinoma: a cross-sectional study.

Endocrine
2026

Clinical and Prognostic Features of Malignant Thyroid Nodules With Atypia of Undetermined Significance Cytology: Evaluation of Nuclear Atypia-Based Subgroups.

Diagnostic cytopathology
2025

Lipidomic Profiling: A Promising New Direction in the Diagnosis and Management of Thyroid Cancer?

Cureus
2025

Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinib.

Cancer chemotherapy and pharmacology
2025

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma.

Molecular imaging and biology
2025

Risk Stratification of Thyroid Nodules 10 mm in Diameter or Less: Strength and Pitfalls of the Ultrasonographic Assessment From a Cross-Sectional Study.

International journal of endocrinology
2026

The Role of External Beam Radiation Therapy in Thyroid Cancer Management: A Scoping Review.

International journal of radiation oncology, biology, physics
2025

[Female reproductive function -after radioiodine therapy for differentiated thyroid carcinoma].

Problemy endokrinologii
2025

Theranostics in nuclear medicine: the era of precision oncology.

Medical oncology (Northwood, London, England)
2025

Thyroid Hormone Withdrawal Yields Higher 131I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large 124I PET/CT Dosimetry Cohort.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2025

A machine learning model for predicting bone and/or lung metastasis in differentiated thyroid carcinoma: enhancing precision in risk stratification.

Frontiers in endocrinology
2025

Impact of Scar on Quality of Life in Well-Differentiated Thyroid Carcinoma: A Systematic Review.

OTO open
2025

Diagnosing Thyroid Lesions Through A Morphology-Molecular Lens: Four Case-Based Lessons From 22nd International Congress of Cytology-Florence 2025.

Diagnostic cytopathology
2025

Differential expression profiles of immunoregulatory genes in anaplastic thyroid carcinomas with a coexistent papillary carcinoma component.

Virchows Archiv : an international journal of pathology
2025

The association between composite inflammatory indicators and the clinicopathological characteristics of differentiated thyroid carcinoma.

Frontiers in molecular biosciences
2025

Effect of Thyroid-Stimulating Hormone Suppression on Bone Mineral Density in Patients with Differentiated Thyroid Carcinoma: A Single Center Retrospective Study.

Journal of bone metabolism
2025

Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.

Thyroid : official journal of the American Thyroid Association
2025

Feasibility of Doing a Safe Robotic Thyroidectomy in a Developing Country and Comparison of 2 Different Techniques.

Indian journal of surgical oncology
2025

Marital status, race/ethnicity, and outcomes in well-differentiated thyroid cancer in the elderly.

Gland surgery
2025

Prolonged response to lenvatinib in a poorly differentiated thyroid carcinoma with leptomeningeal carcinomatosis.

Annales d'endocrinologie
2025

18F-prostate-specific membrane antigen-1007 positron emission tomography / computed tomography detects occult leptomeningeal metastases in poorly differentiated thyroid carcinoma misdiagnosed as vascular mimicry on magnetic resonance imaging.

Polish archives of internal medicine
2025

Cardiovascular risk after total thyroidectomy in patients with differentiated thyroid carcinoma undergoing levothyroxine replacement monotherapy.

Frontiers in endocrinology
2025

High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.

Frontiers in oncology
2025

Comparative analysis of three thyroglobulin immunoassays: analytical performance and clinical implications.

Thyroid research
2025

Diagnostic value of thyroid-related serological indicators and pan-immune-inflammation value for differentiated thyroid carcinoma.

Frontiers in immunology
2025

Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2025

Impact of tumor size on oncological and surgical outcomes in robot-assisted transaxillary surgery for papillary thyroid carcinoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.

Endocrine pathology
2025

Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.

Frontiers in endocrinology
2025

Multifocal papillary thyroid microcarcinomas: is the total tumor diameter associated with the tumor behavior? A retrospective cohort study.

Einstein (Sao Paulo, Brazil)
2025

Optimizing Thyroglobulin Interpretation to Reduce Ultrasound Examinations in the Follow-Up of Differentiated Thyroid Carcinoma.

Clinical endocrinology
2025

Preoperative serum lipids as novel predictors for concomitant thyroid carcinoma in Graves' disease.

PeerJ
2026

Machine Learning Prediction of Recurrence in Pediatric Thyroid Cancer: Malignant Endocrine Tumors Cohort Analysis Using XGBoost and SHAP.

The Journal of clinical endocrinology and metabolism
2025

Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas.

Endocrine pathology
2025

Risk factors and outcomes of metastatic poorly differentiated thyroid carcinoma.

World journal of clinical cases
2025

Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study.

In vivo (Athens, Greece)
2025

Development and validation of a nomogram to predict failure of initial radioactive iodine therapy in differentiated thyroid cancer: a retrospective cohort study.

Scientific reports
2025

Identifying risk factors associated with refractoriness to radioiodine therapy in differentiated thyroid cancer.

Archives of endocrinology and metabolism
2025

The approaches and challenges in the management of differentiated thyroid carcinoma.

Current opinion in endocrinology, diabetes, and obesity
2025

Synchronous Presentation of Type 2 Marine-Lenhart Syndrome and Differentiated Thyroid Carcinoma Manifesting as Thyroid Storm.

Case reports in endocrinology
2025

Hydrogel-driven innovations for targeted delivery, immune modulation, and tissue repair in thyroid cancer therapy.

Frontiers in cell and developmental biology
2025

Postoperative nomogram for predicting involved lymph node in differentiated thyroid carcinoma: an observational study.

Future oncology (London, England)
2025

Evaluation of common genetic risk factors for differentiated thyroid cancer in the Thai population.

Biomedical reports
2025

Enhancing Recurrent Laryngeal Nerve Detection with Neural Autofluorescence in Thyroid Surgery.

Journal of the American College of Surgeons
2025

Association between types of surgery and cancer-specific death in patients with early differentiated thyroid carcinoma: a real-world study.

Frontiers in oncology
2025

Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2025

Risk-adapted therapy in pediatric thyroid cancer: initial experience from a national reference program by the MET group.

European thyroid journal
2025

A Rare Concurrence of Anaplastic and Papillary Thyroid Carcinomas: A Case Report and Literature Review.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2025

The Evolving Role of Radioactive Iodine in Thyroid Cancer Diagnosis and Treatment.

Endocrinology and metabolism clinics of North America
2025

Navigating the complexity of current interventional radiological approaches for distant metastases in thyroid cancer.

Frontiers in endocrinology
2025

Management of Hypoparathyroidism After Total Thyroidectomy for Differentiated Thyroid Cancer in Children and Young Adolescents: Experiences From a Multicenter Cohort in China.

Journal of pediatric surgery
2025

The Role of FNA-CYFRA 21-1 in Cervical Lymph Node Metastasis of Differentiated Thyroid Cancer.

The Laryngoscope
2025

Insulin resistance factors associated with differentiated thyroid carcinoma and malignant cytology: serum thyroxine as an associated factor.

Annals of medicine
2025

Risk factors associated with postoperative complications in pediatric thyroidectomy: A single-center Vietnamese experience.

International journal of pediatric otorhinolaryngology
2025

Survival benefits of primary tumor resection in metastatic differentiated thyroid cancer: an analysis of SEER data.

Scientific reports
2025

Comparison of the surgical outcomes of endoscopic thyroidectomy via a contralateral-axillo-bilateral-breast approach and open thyroidectomy.

Langenbeck's archives of surgery
2025

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy.

Asia Oceania journal of nuclear medicine &amp; biology
2025

Prednisone-aided gross thyroid remnant ablation using 5.55 GBq of radioiodine in patients with differentiated thyroid cancer.

Nuclear medicine communications
2025

Autoimmune thyroiditis in paediatric thyroid cancer: clinical features and outcomes.

European journal of endocrinology
2025

Multicenter analysis of radioactive iodine therapy outcomes after total thyroidectomy for T1-T2 stage papillary thyroid carcinoma with cervical lymph node metastasis in China.

International journal of surgery (London, England)
2025

Impact of the 2015 American Thyroid Association Guidelines on Treatment of Low-Risk Thyroid Cancer.

Laryngoscope investigative otolaryngology
2025

Distinctive hobnail subtype of papillary thyroid carcinoma: a case series and short review of literature.

Hormones (Athens, Greece)
2025

Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves' disease and papillary thyroid cancer.

American journal of surgery
2025

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Development of 3D organoid models to study aggressive thyroid cancers.

European thyroid journal
2025

Circulating Citrate is Elevated During Profound Hypothyroidism: An Observational Study.

Metabolic syndrome and related disorders
2025

Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing.

Cancers
2025

Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
2026

Measurement of Effective Half-life of Iodine-131 to Optimize Safety Release Instructions after Treatment for Patients with Differentiated Thyroid Cancer.

Health physics
2025

Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma?

Endocrine pathology
2025

Integrated microbiome and metabolome analysis reveals a novel interplay between gut microbiota and metabolites in differentiated thyroid carcinoma.

BMC microbiology
2025

Expanding the histologic spectrum of thyroid neoplasms with NTRK1/2/3 or ALK translocation: a single-center retrospective study of 82 cases.

Virchows Archiv : an international journal of pathology
2025

Why so many doses, and why now?

European thyroid journal
2025

Adjuvant External Beam Radiotherapy Reduces Local Recurrence in Poorly Differentiated Thyroid Cancer : A Multicenter Retrospective Cohort Study Describing Outcomes in the Treatment of Resectable Poorly Differentiated Thyroid Cancer.

Annals of surgical oncology
2025

Effectiveness of radioiodine therapy on preventing recurrence in differentiated thyroid carcinoma: a systematic review.

Journal of the Egyptian National Cancer Institute
2025

Challenging diagnosis and treatment of rare paranasal sinus metastasis from thyroid cancer: a case report and literature review.

Frontiers in endocrinology
2025

Hypoxia Inhibitor Improves Iodine Uptake Disorder in Thyroid Cancer Through the hsa_circ_0023990/miR-448/DNMT1/NIS Axis.

Cancer science
Ver todos os 2.145 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Carcinoma da tireoide diferenciado.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Carcinoma da tireoide diferenciado

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.
    Cell death discovery· 2026· PMID 41741426mais citado
  2. The Role of 123I in the Management of Differentiated Thyroid Cancer: A Comprehensive Narrative Review.
    Medical sciences (Basel, Switzerland)· 2026· PMID 41718114mais citado
  3. Multiomics Profiling Reveals Distinct Immunosuppression and Metabolic Dysregulation in Aggressive Subtypes of Thyroid Cancer.
    Molecular &amp; cellular proteomics : MCP· 2026· PMID 41565206mais citado
  4. Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.
    Frontiers in oncology· 2026· PMID 41878530mais citado
  5. ARISK STRATIFICATION AND LONG-TERM MONITORING IN PEDIATRIC THYROID CANCER: PREDICTIVE MARKERS FOR DISEASE PERSISTENCE.
    European thyroid journal· 2026· PMID 41871540mais citado
  6. Poorly differentiated thyroid carcinoma: a case report and literature review.
    Front Oncol· 2026· PMID 41994632recente
  7. Hyperfunctioning distant metastases in high-grade differentiated thyroid carcinoma arising from HRAS-mutated follicular thyroid carcinoma: a case report and literature review.
    Front Endocrinol (Lausanne)· 2026· PMID 41993975recente
  8. Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.
    Cancer Med· 2026· PMID 41992056recente
  9. Predictors of Complete Remission in Differentiated Thyroid Cancer: A Study from the Nuclear Medicine Department of Ibn Rochd Hospital in Casablanca, Morocco.
    Ethiop J Health Sci· 2025· PMID 41988049recente
  10. A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation.
    J Neurooncol· 2026· PMID 41981321recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:146(Orphanet)
  2. MONDO:0015447(MONDO)
  3. GARD:12027(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56013722(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Carcinoma da tireoide diferenciado
Compêndio · Raras BR

Carcinoma da tireoide diferenciado

ORPHA:146 · MONDO:0015447
Prevalência
Unknown
Herança
Not applicable
CID-10
C73 · Neoplasia maligna da glândula tireóide
Ensaios
35 ativos
Início
Adolescent, Adult, Childhood
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0238463
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades